These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31273347)

  • 1. Bromodomains: a new target class for drug development.
    Cochran AG; Conery AR; Sims RJ
    Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomains: A novel target for the anticancer therapy.
    Gokani S; Bhatt LK
    Eur J Pharmacol; 2021 Nov; 911():174523. PubMed ID: 34563497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
    Zhao Y; Yang CY; Wang S
    J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advancements in the Development of non-BET Bromodomain Chemical Probes.
    Clegg MA; Tomkinson NCO; Prinjha RK; Humphreys PG
    ChemMedChem; 2019 Feb; 14(4):362-385. PubMed ID: 30624862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
    Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
    Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding Assays for Bromodomain Proteins: Their Utility in Drug Discovery in Oncology and Inflammatory Disease.
    Zolotarjova NI; Wynn R
    Curr Protoc Pharmacol; 2018 Mar; 80(1):3.16.1-3.16.14. PubMed ID: 30040205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent progress and structural analyses of domain-selective BET inhibitors.
    Divakaran A; Harki DA; Pomerantz WCK
    Med Res Rev; 2023 Jul; 43(4):972-1018. PubMed ID: 36971240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
    Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
    Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting bromodomains: epigenetic readers of lysine acetylation.
    Filippakopoulos P; Knapp S
    Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patent review of BRD4 inhibitors (2013-2019).
    Lu T; Lu W; Luo C
    Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
    [No Abstract]   [Full Text] [Related]  

  • 17. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
    Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
    J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Hewings DS; Rooney TP; Jennings LE; Hay DA; Schofield CJ; Brennan PE; Knapp S; Conway SJ
    J Med Chem; 2012 Nov; 55(22):9393-413. PubMed ID: 22924434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.